NLNeil O’ Leary

Neil O’ Leary

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Neil O’ Leary has a total of 383 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Health literacy and trust in health information sources in Ireland: An online descriptive cross-sectional survey

    by Paula Byrne, Johanna Saia Pope, Neil O’LEary, Nirdesh Bakshi, Declan Devane

    Background: Health literacy is associated with health outcomes, particularly in a digital environment where misinformation is common. Current Irish data on health literacy and trust in health information sources are limited. Objective: To describe health literacy among adults in Ireland using the Health Literacy Questionnaire, examine its associations with demographic, health, and internet-use characteristics, and characterise which health information sources people use and trust. Methods: A descriptive cross-sectional online survey of a convenience sample of 448 adults aged 18 or over and younger than 80 living in Ireland was conducted via Prolific. Participants were English-speaking, had internet access, and at least secondary education. The Health Literacy Questionnaire (HLQ) was administered alongside questions on use of seven named health information source categories and an “other” category, plus free-text responses on most and least trusted sources. Post-stratification weights based on the 2022 Irish Census (age, sex, education) partly reduced differences between the sample and population benchmarks. Regression analyses examined demographic, health, and internet-use predictors. Free-text responses were analysed using AI-assisted and human content analysis. Results: Weighted mean HLQ domain scores varied (Part 1: 2.90–3.01/4; Part 2: 3.39–3.89/5). Older age was associated with better scores for feeling understood by healthcare providers, engaging with providers, and navigating healthcare systems. No clear evidence of sex differences in HLQ scores was observed. Respondents with two or more chronic conditions scored lower across most domains. Healthcare professionals and official health sources were commonly used and most often named as trusted, while general social media was the least trusted (272/446 answers; 61.0%). AI tools were spontaneously cited by 8/448 respondents (1.8%). A small subgroup (9/446 answers; 2.0%), mainly younger women, reported trusting GPs or primary care providers the least. Conclusions: Respondents with multiple chronic conditions had lower scores on several HLQ domains in this weighted online convenience sample. Emerging AI use warrants monitoring.

  • Open Access

    Impact of proton pump inhibitors on efficacy of antiplatelet strategies with ticagrelor or aspirin after percutaneous coronary intervention: Insights from the GLOBAL LEADERS trial

    by Masafumi Ono, Yoshinobu Onuma, Hideyuki Kawashima, Hironori Hara, Chao Gao, Rutao Wang, Neil O'LEary, Edouard Benit, Luc Janssens, Maurizio Ferrario, et al.

    Background: Several studies have suggested that proton pump inhibitors (PPIs) may reduce the antiplatelet effects of clopidogrel and/or aspirin, possibly leading to cardiovascular events.Aims: We aimed to investigate the association between PPI and clinical outcomes in patients treated with ticagrelor monotherapy or conventional antiplatelet therapy after percutaneous coronary intervention (PCI).Methods: This is a subanalysis of the randomized GLOBAL LEADERS trial, comparing the experimental antiplatelet arm (23‐month ticagrelor monotherapy following 1‐month dual antiplatelet therapy [DAPT]) with the reference arm (12‐month aspirin monotherapy following 12‐month DAPT) after PCI. Patient‐oriented composite endpoints (POCEs: all‐cause mortality, myocardial infarction, stroke, or repeat revascularization) and its components were assessed stratified by PPI use as a time‐dependent covariate in patients with the experiment or reference antiplatelet arm.Results: Among 15,839 patients, 2115 patients (13.5%) experienced POCE at 2 years. In the reference arm, the use of PPIs was independently associated with POCE (hazard ratio [HR]: 1.27; 95% confidence interval [CI]: 1.12–1.44) and its individual components, whereas it was not in the experimental arm (HR: 1.04; 95% CI: 0.92–1.19; pinteraction = 0.035). During the second‐year follow‐up, patients taking aspirin with PPIs had a significantly higher risk of POCE compared to those on aspirin without PPIs (HR: 1.57; 95% CI: 1.27–1.94), whereas the risk did not differ significantly irrespective of PPI in ticagrelor monotherapy group (HR: 1.03; 95% CI: 0.83–1.28; pinteraction = 0.008).Conclusions: In contrast to conventional antiplatelet strategy, there were no evidence suggesting the interaction between ticagrelor monotherapy and PPIs on increased cardiovascular events, which should be confirmed in further studies.Clinical Trial Registration: URL: https://clinicaltrials.gov


  • TCTAP A-050 Calcified Plaque Detected on Optical Coherence Tomography With Deep Learning and Cross-Validated With Optical and Ultrasonic Signals: A Complementary Appraisal and Preamble to the Use of Combined IVUS-OCT Catheter

    by Jiayue Huang, Kai Ninomiya, Shengxian Tu, Shinichiro Masuda, Jouke Dijkstra, Miao Chu, Daixin Ding, Sean O. Hynes, Neil O’lEary, William Wijns, et al.


  • Open Access

    Contents

    by Mohammed El Mahdiui, Pieter van der Bijl, Rachid Abou, Rodolfo De, Paula Lustosa, Tina Retzlaff, Johannes Schmucker, Alberto Luis, Marin Mata, Leonardo Knijnik, et al.

  • Open Access

    Graphical comparisons of relative disease burden across multiple risk factors

    by John Ferguson, Neil O’lEary, Fabrizio Maturo, Salim Yusuf, Martin O’dOnnell

    Background: Population attributable fractions (PAF) measure the proportion of disease prevalence that would be avoided in a hypothetical population, similar to the population of interest, but where a particular risk factor is eliminated. They are extensively used in epidemiology to quantify and compare disease burden due to various risk factors, and directly influence public policy regarding possible health interventions. In contrast to individual specific metrics such as relative risks and odds ratios, attributable fractions depend jointly on both risk factor prevalence and relative risk. The relative contributions of these two components is important, and usually needs to be presented in summary tables that are presented together with the attributable fraction calculation. However, representing PAF in an accessible graphical format, that captures both prevalence and relative risk, may assist interpretation. Methods: Taylor-series approximations to PAF in terms of risk factor prevalence and log-odds ratio are derived that facilitate simultaneous representation of PAF, risk factor prevalence and risk-factor/disease log-odds ratios on a single co-ordinate axis. Methods are developed for binary, multi-category and continuous exposure variables. Results: The methods are demonstrated using INTERSTROKE, a large international case control dataset focused on risk factors for stroke. Conclusions: The described methods could be used as a complement to tables summarizing prevalence, odds ratios and PAF, and may convey the same information in a more intuitive and visually appealing manner. The suggested nomogram can also be used to visually estimate the effects of health interventions which only partially reduce risk factor prevalence. Finally, in the binary risk factor case, the approximations can also be used to quickly convert logistic regression coefficients for a risk factor into approximate PAFs.


  • Orthostatic blood pressure variability is associated with lower visual contrast sensitivity function: Findings from The Irish Longitudinal Study on Aging

    by Bláithín Ní Bhuachalla, Christine A. McGarrigle, Neil O'LEary, Kwadwo Owusu Akuffo, Tunde Peto, Stephen Beatty, Rose Anne Kenny


  • Open Access

    Joint association of urinary sodium and potassium excretion with cardiovascular events and mortality: prospective cohort study

    by Martin O’donnell, Andrew Mente, Sumathy Rangarajan, Matthew J McQueen, Neil O’leary, Lu Yin, Xiaoyun Liu, Sumathi Swaminathan, Rasha Khatib, Annika Rosengren, et al.

    Objective To evaluate the joint association of sodium and potassium urinary excretion (as surrogate measures of intake) with cardiovascular events and mortality, in the context of current World Health Organization recommendations for daily intake (3.5 g potassium) in adults. Design International prospective cohort study. Setting 18 high, middle, and low income countries, sampled from urban and rural communities. Participants 103 570 people who provided morning fasting urine samples. Main outcome measures Association of estimated 24 hour urinary sodium and potassium excretion (surrogates for intake) with all cause mortality and major cardiovascular events, using multivariable Cox regression. A six category variable for joint sodium and potassium was generated: sodium excretion (low (5 g/day) sodium intakes) by potassium excretion (greater/equal or less than median 2.1 g/day). Results Mean estimated sodium and potassium urinary excretion were 4.93 g/day and 2.12 g/day, respectively. After a median follow-up of 8.2 years, 7884 (6.1%) participants had died or experienced a major cardiovascular event. Increasing urinary sodium excretion was positively associated with increasing potassium excretion (unadjusted r=0.34), and only 0.002% had a concomitant urinary excretion of 3.5 g/day of potassium. A J-shaped association was observed of sodium excretion and inverse association of potassium excretion with death and cardiovascular events. For joint sodium and potassium excretion categories, the lowest risk of death and cardiovascular events occurred in the group with moderate sodium excretion (3-5 g/day) and higher potassium excretion (21.9% of cohort). Compared with this reference group, the combinations of low potassium with low sodium excretion (hazard ratio 1.23, 1.11 to 1.37; 7.4% of cohort) and low potassium with high sodium excretion (1.21, 1.11 to 1.32; 13.8% of cohort) were associated with the highest risk, followed by low sodium excretion (1.19, 1.02 to 1.38; 3.3% of cohort) and high sodium excretion (1.10, 1.02 to 1.18; 29.6% of cohort) among those with potassium excretion greater than the median. Higher potassium excretion attenuated the increased cardiovascular risk associated with high sodium excretion (P for interaction=0.007). Conclusions These findings suggest that the simultaneous target of low sodium intake (3.5 g/day) is extremely uncommon. Combined moderate sodium intake (3-5 g/day) with high potassium intake is associated with the lowest risk of mortality and cardiovascular events.


  • Orthostatic hypertension as a risk factor for age-related macular degeneration: Evidence from the Irish longitudinal study on ageing

    by Bláithín Ní Bhuachalla, Christine A. McGarrigle, Neil O'LEary, Kwadwo Owusu Akuffo, Tunde Peto, Stephen Beatty, Rose Anne Kenny


  • Open Access

    Examining the utility of cystatin C as a confirmatory test of chronic kidney disease across the age range in middle-aged and older community-dwelling adults

    by Mark Canney, Donal J Sexton, Neil O’lEary, Martin Healy, Rose Anne Kenny, Mark A Little, Conall M O’sEaghdha

    Background: Cystatin C has been proposed as a confirmatory test of chronic kidney disease (CKD). This is most applicable to older individuals with CKD, the majority of whom have a creatinine-based estimated glomerular filtration rate (eGFR) of 45–59 mL/min/1.73 m2 (CKD stage 3a). We sought to examine the utility of cystatin C as a confirmatory test of CKD across the age range in the general population of older adults. Methods: Cross-sectional analysis of 5386 participants from The Irish Longitudinal Study on Ageing, a cluster-sampled national cohort of community-dwelling adults aged ≥50 years. Cystatin C and creatinine were measured simultaneously using standardised assays. Using generalised additive models, we modelled the distributions of creatinine and cystatin C per year of age from four distributional parameters: location, dispersion, skewness, kurtosis. Among participants with CKD stage 3a, we estimated the predicted probability of cystatin C eGFR 2 (‘confirmed CKD’) as a function of age. Results: Median age was 62 years, 53% were female and median cystatin C eGFR was 80 mL/min/1.73 m2. We observed progressive variability in cystatin C with increasing age. Compared with creatinine, cystatin C levels rose sharply beyond the age of 65. Among participants with CKD stage 3a (n=463), the predicted probability of ‘confirmed CKD’ increased steadily with age, from 15% at age 50 to 80% at age 80. Conclusions: The clinical utility of cystatin C may be maximised in middle-aged individuals, in whom the distribution of cystatin C is less variable than older adults, and the pretest probability of confirming CKD is lower.